About: Clinical Evaluation of the cobas SARS-CoV-2 Test and a Diagnostic Platform Switch during 48 Hours in the Midst of the COVID-19 Pandemic

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Clinical Evaluation of the cobas SARS-CoV-2 Test and a Diagnostic Platform Switch during 48 Hours in the Midst of the COVID-19 Pandemic Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Clinical Evaluation of the cobas SARS-CoV-2 Test and a Diagnostic Platform Switch during 48 Hours in the Midst of the COVID-19 Pandemic
Creator	Petrovec, Miroslav Uršič, Tina Poljak, Mario Korva, Miša Gašper, Nataša Komloš, Kristina Sagadin, Martin
Source	Medline; PMC
abstract	Laboratories are currently witnessing extraordinary demand globally for sampling devices, reagents, consumables, and diagnostic instruments needed for timely diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. To meet diagnostic needs as the pandemic grows, the U.S. Food and Drug Administration (FDA) recently granted several commercial SARS-CoV-2 tests Emergency Use Authorization (EUA), but manufacturer-independent evaluation data are scarce. We performed the first manufacturer-independent evaluation of the fully automated sample-to-result two-target test cobas 6800 SARS-CoV-2 (cobas) (Roche Molecular Systems, Branchburg, NJ), which received U.S. FDA EUA on 12 March 2020. The comparator was a standardized 3-h SARS-CoV-2 protocol, consisting of RNA extraction using an automated portable instrument, followed by a two-target reverse transcription real-time PCR (RT-PCR), which our laboratory has routinely used since January 2020 [V. M. Corman, O. Landt, M. Kaiser, R. Molenkamp, et al., Euro Surveill 25(3):pii=2000045, 2020, https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045]. cobas and the comparator showed overall agreement of 98.1% and a kappa value of 0.95 on an in-house validation panel consisting of 217 well-characterized retrospective samples. Immediate prospective head-to-head comparative evaluation followed on 502 samples, and the diagnostic approaches showed overall agreement of 99.6% and a kappa value of 0.98. A good correlation (r(2) = 0.96) between cycle threshold values for SARS-CoV-2-specific targets obtained by cobas and the comparator was observed. Our results showed that cobas is a reliable assay for qualitative detection of SARS-CoV-2 in nasopharyngeal swab samples collected in the Universal Transport Medium System (UTM-RT) (Copan, Brescia, Italy). Under the extraordinary circumstances that laboratories are facing worldwide, a safe diagnostic platform switch is feasible in only 48 h and in the midst of the COVID-19 pandemic if carefully planned and executed.
has issue date	2020-05-26(xsd:dateTime)
bibo:doi	10.1128/jcm.00599-20
bibo:pmid	32277022
has license	cc-by
sha1sum (hex)	8d056c2bf77c4e7781e14388ec17ee69afb6dd4f
schema:url	https://doi.org/10.1128/jcm.00599-20
resource representing a document's title	Clinical Evaluation of the cobas SARS-CoV-2 Test and a Diagnostic Platform Switch during 48 Hours in the Midst of the COVID-19 Pandemic
has PubMed Central identifier	PMC7269406
has PubMed identifier	32277022
schema:publication	J Clin Microbiol
resource representing a document's body	covid:8d056c2bf77c4e7781e14388ec17ee69afb6dd4f#body_text
is schema:about of	named entity 'timely' named entity 'received' named entity 'U.S.' named entity 'Laboratories' named entity 'evaluation' named entity 'automated' named entity 'Molecular' named entity 'INDEPENDENT' named entity 'DIAGNOSTIC' named entity 'KAPPA' named entity 'AUTOMATED' named entity 'WITNESSING' named entity 'DEVICES' named entity 'GLOBALLY' named entity 'https' named entity 'SARS-CoV-2' named entity 'infection' named entity 'Branchburg' named entity 'Kaiser' named entity 'diagnosis' named entity 'commercial' named entity 'reverse transcription' named entity 'Emergency Use Authorization' named entity 'RT-PCR' named entity 'FDA' named entity 'infection' named entity 'real-time PCR' named entity 'laboratory developed tests' named entity 'rhinovirus' named entity 'nasopharyngeal swab' named entity 'U.S. FDA' named entity 'SARS-CoV-2' named entity 'COVID-19 testing' named entity 'Brescia' named entity 'nasopharyngeal swab' named entity 'viruses' named entity 'tested for the presence' named entity 'SARS-CoV-2' named entity '0.98' named entity 'follow-up' named entity 'RdRp' named entity 'sarbecovirus' named entity 'human parainfluenza virus' named entity 'primers' named entity 'gold standard' named entity 'genome' named entity 'Branchburg' named entity 'high-throughput' named entity 'conserved region' named entity 'positive control' named entity 'COVID' named entity 'SARS-CoV-2' named entity 'RdRp' named entity 'ORF1' named entity 'Microsoft' named entity 'sarbecovirus' named entity 'U.S. FDA' named entity 'SARS-CoV-2' named entity 'McNemar's test' named entity 'RNA' named entity 'gene' named entity 'EUA' named entity 'viral load' named entity 'SARS-CoV' named entity 'ORF1' named entity 'virus' named entity 'nasopharyngeal' named entity 'Copan' named entity '95% CI' named entity 'Grand Island, NY' named entity 'Roche' named entity 'influenza virus' named entity 'Roche Applied Science' named entity 'coronavirus' named entity 'follow-up'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software